everyone quarter financial to conference Thanks, results call and highlights. to XXXX our our first welcome operating discuss And Bob.
on are me Operating call Officer; Senior Officer. Levine, Ph.D, Chief Scientific and Joining Financial Mitch Lyndal today's Officer; Parker, Al Chief Chief Hesterberg
We question-and-answer the XXXX cancer lung will diagnostic session. validation started has biopsy available year liquid all during completion our a studies successful for test. OncoCyte. the been XXXX our transformative of R&D We be with DetermaVu,
progress remain completing commercial half have in subsequent towards second of development, DetermaVu we year. the product we made With for availability on this the track of
review commence proceeds, mid-February, and In R&D to our program raise well system leaving complete completed the interrogation and of our brief of development addition, other leverage for DetermaVu. balance steps development update our of of immune our an recap accomplishments Today We'll also remaining and million path the and unique we'll cancer of with strengthening we beginning the successful finish $XX provide to brief positioned in equity a indications. us on net commercialization of a towards sheet commercialization recent financial. approach a and expanded
the to SX whether robust of biopsies expensive, developed decision Ion validation short, CT quickly mRNA we blood study XX% Torrent with risky R&D is nodules. confirmatory to value study ensure the are patient liquid a lung to use by a a results. the commercially that is of determining, lung the to confidence XX%. analyzed from and XXX XXXX, year, scan and determined suspicious best utilizing facilitate is algorithm our biomarkers, interval diagnosis. change of biopsy consistent, announced DetermaVu the proposition of Fisher study transition reduce demonstrated with lung and is platform with The number next-generation nodule. to following biopsy samples, is developing to lung non-invasive specificity These diagnosed. for our solidified Company's reminder, confidence In with the we Late patient a of XX% a last R&D study. GeneStudio XX% in DetermaVu XX% with benign results successful followed DetermaVu XX% test a previously study. to validation reproducible viable sensitivity our optimized Thermo a test XX% and blinded designed clinical fundamentally necessary cancer positive that dose to tissue of before way That class results As XX% algorithm is cancer we in potential DetermaVu In making interval low
is statistical a correctly test reminder, performance the that a the the are sensitivity and sensitivity or that will interval test nodules of that malignant of by range. there specificity CI A confidence final the measures correctly chance percentage identified. are measuring stated test measuring identified percentage benign suggests be XX% with and performance, As within of XX% specificity, module
as the community. well We of one with whole XX of medical forward versus will XXXX the to medical look data. gene Dallas. our results be presentation a which being is benign to conferences, and of of regarded Thoracic these pulmonary Conference, broader Study these Validation the May these be expression multidisciplinary presenting Society will we of in largest And malignant American for XX late scientific blood the diagnosis Prospective held at presentation nodules abstract sharing breaking poster form May International The first a and Blinded entitled, classifier results most
key DetermaVu, characteristics the SA is platform substances. system required for established precision, clinical the the DetermaVu guidelines analytical reproducibility month, performance completion study the limit The the last and Fisher for sequencing analytical utilizing validation next the Thermo the Just we CLIA of study announced standards, testing successful Laboratory. Analytical the next development milestone. interference in are in cover of and OncoCyte’s established validation generation institute observatory quantification, validation
part robust studies in validation studies seen CLIA validation our conducted are blood tested samples, and study commercialization. the successfully, study. and of Company's data initiated equivalent this R&D necessary analytical validation these real validation two essaying when and CLIA protocols results includes CLIA XXX encouraged in study, of aims of accuracy, previously study. validation performance a clinical we we to the setting. look to supports to the the previously In of the as all Lab with our quickly in R&D Laboratory forward completion remaining that confirm completed of analytical study. We performance the now to have report We reproducibility the from the After CLIA This study, CLIA prior are which approximately study, one precision reporting specific to Laboratory is validation validated demonstrate laboratory Laboratory staff world test DeterminaVu
we blinded, the patient the will samples clinical final Assuming of remaining prospectively Lab about of validation. to specificity the blood validation clinical analyze CLIA commercialization completion validation prior with the setting. final steps collected and successful will study, XXX study, In sensitivity our tests, begin CLIA confirmation we in
samples plus have bar physician confidence and error to will needed final we collected we prospectively is which range reduce we adoption. studies or about proceed the can the freezers patient validation believe and our about are DetermaVu's blinded we run and minus the samples. for in our XXX for specificity sensitivity, X%, the validation blood These of to intended all Importantly, need R&D blinded that performance accuracy already studies, two clinical this step. study, of rapidly have Between through
Let's two this track call. later touch these upon detail in mid-XXXX. on the We studies to in greater remain by complete remaining
the half completion, available commercially of this we plan year. in Successful Assuming second on making DetermaVu
of progress recent are our efficient and execution entire of proud market. the bring are to for the We to to grateful studies DetermaVu OncoCyte the required team rapid and the
At exclusive unique presence harnesses breakthrough While scientific excited field to perspective. represent like we that these significance which sensitivity results scientific also we're to That's early our cancer. system's thus from a a reminder for the true a the DetermaVu's OncoCyte by excited we've believe of our by it. far, approach I'd cancer diagnosis. been liquid the results in provide brief progress the biopsy remarkable immune about of equally now of
methodologies DNA, late the this of stage DNA direct for to cancer. circulating shown immune and because earliest cell stages expression a in system in in early cells the response Likely changes in blood of approach, from cancer, tumor system hard tumor at detection have detects tests we they're in the in to the cancer, Our call we of reliable which in all simple sample. And immune gene blinded interrogation, We early approach companies to are as detection stage the blood the cancer. applying detect be and lung was just such first these Other or diagnosis. remain diagnose alternative it cancer for that successful can diagnosis. Well, components early enough some lung lung that reliably our study reproducibly the cancer. type succeed blood. They unsuccessful may stage believe stage
trying are detecting of detect directly our body's we succeed to of difficult where to an have sensitive the unique highly small very allowed response to approach many This instead, immune amplified, find is So, the cancer of by system. has what us and to cancer, instead traces competitors failed.
up. this back results Our
samples studies approach of our early malignancies. very millimeters, with across solid also patients stage indicative particularly our cancer. interrogation applied of nodules be early one potential increasingly by from We're All of tumors, the immune stage XX excited generally are the from which no broadly are to than larger system for
we R&D for future look patient areas are next of determine the the our commercialization While actively developing also our on to OncoCyte. commercial forward we our our remain cancer, focus, for to of for focused DetermaVu activities, plans, expand broadly. completing based technology opportunity about steps on both lung next steps plans we for need and We updates providing rapidly as more remaining
will I'd address how or of worldwide. a in most to cancer and DetermaVu with Lung cancer and of diagnostics diagnosed move by patients, the both the death, late disease. doctors reimbursement, we has reminder allow cancer US prolonging remains have potential challenges cause the stage patients lung significant life. Detecting until early chance leading faced provide not earlier treatment Before like to of brief are a to peers. they one because and the saving in commercialization cancer better for Generally
problem collapsed states, intensive important methods of risky, of x-rays, note to in X% with scans on the high are as and or death. CT biopsies tissue rates main unit it's by detection to low up followed care current results Lung lies. of such cases, rely And that and is lungs, in However, complications, biopsy. where this dose
likelihood by published in XX% In of biopsies found complication patients American JAMA, the Association a that fact, was rate study of rate over high major of Journal lung outcomes Medical which old. examined for recently and complication most that this estimates emphasizes in underwent probability of highlighted in the associated a complications XXX,XXX confirming higher is under serious and and patients previous rate the with cancer. patients, This greater of complications years lung Medicare XX% biopsies XX is the than patients than of
the clinicians. avoiding potential spend to with clear would a system. benefits for the malignancy This also DetermaVu the the are and and the eliminate Medicare important a the With in will to risk not little a time real-world expensive. patient DetermaVu data lung has number in also is cost DetermaVu patients It's biopsies help patient can saving biopsy DetermaVu risks average to significant likely healthcare impact healthcare physician. increased why and complications should biopsy. an to life, Economics for diagnostics study and is firm, considerable other as achieved a cost test I This like clinicians are algorithm. of determine and and a detected Health patients. cost blood is This to without have use least note screening a would savings and lead DetermaVu patients that of for that means attractive $XX,XXX. sensitivity of This have which nodules to differentiated data explaining the without why the biopsy, Beyond to specificity unnecessary by while extremely Where a have are undergoing simple of system. it early the to procedures has means to from nearly independent valuable unnecessary of leading physicians also are According is greater clinical detection to likely they an have to patients reported that
from study. As data. smoking the biological nodule independent, clinical lung, information to such and as the patient's DetermaVu lung assessment margins will incremental which it the new provide the asked for like the data and I and already of course be. so the size risk to as tool recently risk the of would clinical characteristics of been would But within doctor of I want beyond to of speculate with have. and result by results interval the study significance resonates haven't of our an R&D and even that the cancer decision-making interval there history for to This suggests validation will XX% health we the is provides yet, available stratification public can’t a doctors what announced investors have final final confidence testing stated we like clinical about validation that probability XX% think confidence a sample I everyone we our and remind be range. don’t know. the we begun The
you was XX% XX% for As interval specificity to to sensitivity and confidence recall XX%. the will XX% for
and expand this So market what policy American Molecular We which is chest physicians. of key diagnostic confirm detection. biomarker ready Cancer, that cancer need This lower lung a we sensitivity to to very significantly research will published range cancer on be as a states excited at the validation, official XX%. doctors to the Early on provide biomarker Society. for and a in American the and use. this opinion required for for by level for these will molecular prior within sensitivity commercial We're of of reported XX% sensitivity, our statement to I clinical an leaders a cancer mean for does patients determined the highlighting the Thoracic specificity Today XX% which market Evaluating believe of diagnostic numbers need for at specificity, will highlighted believe clinically Thoracic use from the required at lower of confidence of Biomarkers need determine a interval Detection evidence provides them allowing lung least independently that R&D would substantiate that are of to market previously product early doctors? far DetermaVu The usefulness policy the to by The clinical sensitive survey useful. for we parameters successful statement, would guidance range exceed test, least be our and with our that specificity policy entitled DetermaVu the a in Consequently, of of thus and levels the based Lung are support like lung the the highly of committee for Society clinical when boundaries would biopsy. be confidently specific comes reported detection that
the lung We depending of $X.X to estimated opportunities addressable that large to briefly Now number physician utilization, touch DetermaVu. rate $X US an upon that of market penetration. alone, there benefit would on scope and believe reimbursement commercial of the from for total billion DetermaVu. is patients These the billion nodule the with in market figures emphasize
larger As to now a X those with size are biopsy But nodules of nodules. nodules small follow the to millimeter physicians to the DetermaVu of end of millimeters Lung-RADS in the nodules or be testing opportunity range for in note electing incidence well see of physicians malignant millimeter on X based on we biopsy an patients who DetermaVu as the in nodules. lung more many potential utilization in those statistically X guidelines, the likely because scope
DetermaVu One confirmatory regardless is for low detected of the guidance use test the of a adapted dose size scan. of see care for our if making by CT to nodule in of the goals recommendations for a patient as
XXXX commercial team U.S. promote remains sales and build making professionals commercially liaison to team US we science and building independently plan reps, talented of a have early of We're of support in approximately it marketing in available, targeted in and to pulmonologists to the Our DetermaVu in professionals, medical a launch the staff. small among the stages DetermaVu begun patient preparation effectively
as our future. finalized provide they the commercial are in will to near We plan updates
public one commercial real health the move the They need reimbursement commercialization broad the use utility and will years address. will for Medicare Company large strategy, lowers after reimbursement healthcare patients securing for and conducting world, and favorably towards step Thus are an the we're plans. diagnostic course recognize focus to DetermaVu system. of actual a payers, follow from to far private for health we by two have commercially successful unmet for a it commercialization developed patients clinic highly XX a and post we view a DetermaVu a in this, how and all measuring essentials study results costs outcomes for includes encouraged to test. accomplish Of comprehensive major To working improve which
generate be as However, with revenues other the we before one years and before I said given reality space in as it that DetermaVu. diagnostic two of would reimbursement companies diagnostic believe from we significant the to
So diagnosis. fundamentally as months and to approach cancer diagnosis we biopsy our this paradigm physicians this to explore financials. improvements of first believe product be of would our leveraged stage unique from are for for change and for treatment turn early We over is pipeline for Levine time Mitch? only a cancer can time I I lung the a leading this start our At commercial call review the liquid patients, tests meaningful transformational to are OncoCyte. can DetermaVu said convinced away of beginning We're call Mitch the to that like of payer. for revolutionary and
